ClinicalTrials.gg
Not yet recruitingNCT07714395Updated Jul 20, 2026

Evaluate Preliminary Anti-tumor Activity of Elraglusib in Adult Participants With Advanced Solid Tumors

A Phase 1/2 interventional study of Elraglusib Oral Tablets in Advanced Malignant Solid Tumor, sponsored by Actuate Therapeutics Inc.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-20.

Sponsored by Actuate Therapeutics Inc. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This study is being done to test the safety of elraglusib when taken once a day and to assess:

  • How the body processes the drug (pharmacokinetics)
  • Assess potential effects of the drug on heart rhythm
  • Find the highest daily dose that can be given without causing side effects
Read the detailed description

The study is a Phase 1/2, open label, dose escalation, safety, PK, PD and antitumor activity study of elraglusib tablets in participants aged 18 years or older with a histologically or cytologically confirmed diagnosis of advanced metastatic or progressive malignant solid tumors who are intolerant of or the malignancy is refractory to established therapy know to provide clinical benefit for their condition, or the malignancy has relapsed after standard therapy. Participants must have at least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 measured by computed tomography (CT) scan or MRI to be eligible.

The study's primary objective is to determine the MTD or MAD and DLTs of elraglusib tablets administered daily. The secondary objectives are to study the PK of elraglusib tablets, to evaluate preliminary antitumor activity of elraglusib when administered as tablets, and to establish the RDEs of elraglusib tablets in subsequent development.

02

Conditions studied

  • Advanced Malignant Solid Tumor

Keywords

  • Phase 1/2
  • Elraglusib
  • Elraglusib Oral tablet
  • Solid Tumor
  • GSK3beta
  • Glycogen Synthase Kinase 3 Beta inhibitor
  • ATR/Chk1
03

In context

Lead sponsor

Actuate Therapeutics Inc. is the lead sponsor of 5 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must meet all of the following criteria to be eligible for inclusion in the study:

    1. Able to understand and voluntarily sign a written and is willing and able to comply with the protocol requirements including scheduled visits, treatment plan, laboratory tests and other study procedures
    2. Age ≥ 18 years
    3. Has or cytologically confirmed diagnosis of advanced or progressive solid tumor characterized by one or more of the following:

      1. Participant is intolerant of existing therapy(ies) known to provide clinical benefit for their condition
      2. is to existing therapy(ies) known to potentially provide clinical benefit
      3. Malignancy has relapsed after standard therapy
      4. Participant has to or declines standard therapies
    4. Has at least 1 per (RECIST) v1.1, measured preferably by computed tomography (CT) scan or magnetic resonance image (MRI)
    5. Has laboratory function within specified parameters (may be repeated):

      1. Adequate bone marrow function: (ANC) ≥ 1.5 x 109/L; ≥ 8.5 g/dL, ≥ 100 x 103/μL
      2. Adequate liver function: transaminases (/ alanine aminotransferase, AST/ALT) and alkaline phosphatase ≤ 2.5 x (ULN) or ≤ 5 x the ULN if liver metastases are present; total ≤ 1.5 x ULN or ≤ 3.0 x ULN if elevations are due to underlying disease or concomitant medication/diseases
      3. Adequate renal function: BSA-adjusted (GFR) ≥ 60 mL/min determined by multiplying estimated GFR by participant's body surface area (BSA) and dividing by 1.73
    6. Eastern Co-operative Oncology Group () Performance Status (PS) ≤ 2
    7. Women of must have a negative baseline blood or urine pregnancy test within 72 hours of first dose of study drug. Women may be neither breastfeeding nor intending to become pregnant during study participation and must agree to use effective methods (hormonal or barrier method of birth control, or true abstinence) for the duration of study participation and in the following 6 months after discontinuation of study treatment
    8. Male participants with partners of childbearing potential must take appropriate precautions to avoid fathering a child from screening until 6 months after discontinuation of study treatment and use appropriate barrier contraception or true abstinence
    9. Must not be receiving any other medicinal product

Exclusion criteria

Exclusion Criteria:

  • Participants who meet any of the following criteria will be excluded from the study:

    1. Pregnant or lactating
    2. Known to be hypersensitive to any of the components of elraglusib tablets or to the used in its formulation
    3. Has not recovered from toxicities as a result of prior anticancer therapy, except alopecia and/or infertility. Recovery is defined as ≤ Grade 2 severity per (CTCAE), v6.0
    4. The following risk factors for abnormal heart rhythms/:

      1. A history of Torsade de pointes (TdP), other ventricular arrhythmias, or long QT syndrome
      2. A QT or QT interval corrected using Fridericia's formula (QTcF) > 470 msec at Screening from triplicate ECGs
    5. Has significant cardiovascular impairment: congestive heart failure greater than (NYHA) Class II, family history of long QT syndrome, unstable angina, or stroke within 6 months of the first dose of study therapy
    6. Has had a myocardial infarction within 6 months of the first dose of study therapy or has abnormalities that are deemed medically relevant by the investigator
    7. Has symptomatic or as assessed by CT scan or MRI. Participants with stable brain metastases or leptomeningeal disease are eligible provided they have not required new treatments for this disease in a 28-day period before the first dose of study drug, and anticonvulsants and are at a stable dose for a period of 14 days prior to the first dose of study drug
    8. Has had major surgery within 14 days prior to study entry or is planned to have major surgery during the course of the study (major surgery may be defined as any invasive operative procedure in which an extensive resection is performed, e.g., a body cavity is entered, organs are removed, or normal anatomy is altered. In general, if a mesenchymal barrier is opened [pleural cavity, peritoneum, meninges], the surgery is considered major)
    9. Has any medical and/or social condition which, in the opinion of the Investigator or Medical Monitor would preclude study participation
    10. Previous anticancer therapies with any of the following:

      1. Small molecule ≤ 14 days or 5× the terminal phase elimination t1/2, whichever is shorter, prior to the first dose of study drug
      2. Cytotoxic chemotherapy ≤ 14 days prior to the first dose of study drug
      3. Treatment with biologics (e.g., monoclonal antibodies, bispecific antibodies, cancer vaccines) ≤14 days prior to the first dose of study drug
      4. Broad field radiation therapy ≤14 days prior to the first dose of study drug
      5. Focal radiation therapy (including palliative) ≤ 7 days prior to the first dose of study drug
      6. Systemic and topical corticosteroids ≤ 7 days prior to the first dose of study drug
    11. Use of sensitive substrates of with a narrow therapeutic from 14 days prior to first administration of study drug, during the study, and until Safety Follow-up Visit.
    12. Use of strong inhibitors or inducers of CYP2C19, CYP1A2 and CYP3A4 from 14 days prior to first administration of study drug, during the study, and until Safety Follow-up Visit.
    13. Use of inhibitors or inducers of major drug transporters (i.e., OATP1B1, OATP1B3, OCT1, OCT2 and MATE1/2K) from 14 days prior to first administration of study drug, during the study, and until the Safety Follow-up Visit.
    14. Concomitant participation in another clinical study with study drug(s) or device
    15. Unable to swallow a tablet or has any condition(s) that, in the opinion of the treating investigator, may affect gastrointestinal absorption
    16. Considered to be a member of a vulnerable population (for example, prisoners)
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Elraglusib Monotherapy Dose escalation/de-escalation

    Elraglusib 250 mg tablets will be administered once daily with food in 21-day cycles. DG-1: 125mg (Days 1, 3, 5 of a 21 day cycle) DG1: (Starting Dose) 125 mg/QD for 21 days DG2: 250mg/QD for 21 days DG3: 500mg QD for 21 days DG4: 750mg/QD for 21 days, Dosing will continue until MTD or MED is identified. Any higher dose levels which are explored will not exceed 50% increment relative to the prior cohort rounded down to the nearest 250 mg dose (or 125 mg dose if necessary).

    Drug: Elraglusib Oral Tablets

Interventions

06

What researchers measure

Primary outcomes

  1. To determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and dose-limiting toxicities (DLTs) of elraglusib tablets

    Dose escalation/de-escalation decisions and the MTD will be determined at the end of Cycle 1 (each cycle is 21/28days).

    Time frame: Determined at the end of Cycle 1 (each cycle is 21/28days) for each dose group tested up to 24 moths.

Secondary outcomes

  1. Pharmacokinetic Assessment

    Characterize Elraglusib Cmax

    Time frame: From date of first dose through completion of Initial 21-day cycle. (Assessed Cycle 1 Only-up to 28 days) for each dose cohort, up to 24 months.

  2. Pharmacokinetic Assessment

    Characterize Tmax

    Time frame: From date of first dose through completion of Initial 21-day cycle. (Assessed Cycle 1 Only-up to 28 days) for each dose cohort, up to 24 months.

  3. Pharmacokinetic Assessment

    Assessment of half-life (t1/2), area under the plasma concentration-time curve from time 0 to time t (AUC0→t).

    Time frame: From date of first dose through completion of initial 21-day cycle. (Assessed Cycle 1 Only-up to 28 days) for each cohort, up to 24 months.

  4. Pharmacodynamic Assessment

    Assess peripheral blood mononuclear cells (PBMCs, both cryopreserved and flash frozen).

    Time frame: From Day 1 Dosing through completion of Day 21 of Cycle 1 only. (Assessed Cycle 1 only, up to 28-days) for each dose cohort up to 24 months.

  5. Pharmacodynamic Assessment

    Plasma will be collected to analyze cfDNA.

    Time frame: From date of first dose through completion of Initial 21-day cycle. (Assessed Cycle 1 Only-up to 28 days) for each dose cohort, up to 24 months.

  6. Pharmacodynamic Assessment

    Plasma will be collected to analyze cytokines/chemokines.

    Time frame: From date of first dose through completion of Initial 21-day cycle. (Assessed Cycle 1 Only-up to 28 days) for each dose cohort, up to 24 months.

  7. Tumor Assessments

    Tumor response based on assessment of target and non-target lesions according to response evaluation criteria in solid tumors (RECIST) criteria.

    Time frame: Baseline and per standard of care every 9 (±1) weeks during treatment and during follow-up through disease progression for unto 30 months.

  8. Electrocardiogram (ECG)

    Electrocardiograms will be collected to assess cardiac repolarization (QT) interval.

    Time frame: Participation will be from Date of Screening through completion of the End of Treatment Visit, (EoT Visit), for up to 30 months. (Phase 1 Only)

  9. Electrocardiogram (ECG)

    Assessment of cardiac repolarization (QTc) interval.

    Time frame: Participation will be from Date of Screening through completion of the End of Treatment Visit, (EoT Visit), for up to 30 months. (Phase 1 Only)

  10. Safety Assessments

    Frequencies and severities of adverse events (AEs)/TEAEs, including DLTs, serious adverse events (SAEs), and laboratory abnormalities that occur in Cycle 1 as well as in later treatment cycles will be assessed for all patients.

    Time frame: From date of randomization until 30 days after receiving their last dose of study drug/completion of the End of Treatment Visit for up to 30 months.

  11. Number of participants with clinically significant changes in laboratory parameters, vital signs, and physical examinations.

    Blood and urine samples will be collected for analysis of lab parameters. Vital signs, physical examinations and organ-specific parameters will be collected at specified time points

    Time frame: Participants will be tracked from Date of first dose through completion of end of study/Treatment visit for up to 30 months.

Other outcomes

  1. Exploratory Endpoint Evaluation

    Progression-free survival (PFS) \[Phase 1 only\]

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first. Patient will be assessed up to 30 months or up to 12 months after patient receives last dose of study drug.

  2. Exploratory

    Overall survival (OS) (Phase 1 Only)

    Time frame: From date of randomization until the date of first documented progression, date of death from any cause, whichever came first, assessed up to 12 months after receiving their last dose of study drug.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Jul 2029, 33 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2026
First posted
Jul 20, 2026
StartEst.
Oct 2026
Primary completionEst.
Jul 2029
CompletionEst.
Dec 2029
Last update
Jul 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07714395
Lead sponsor
Actuate Therapeutics Inc.
Responsible party
Sponsor
First posted
Jul 20, 2026
Start date
Oct 2026 (estimated)
Primary completion
Jul 2029 (estimated)
Completion
Dec 2029 (estimated)
Last update
Jul 20, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elraglusib

Start the discussion